Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07005453

Accuracy and Sustainability of SCALE-EYE Evaluation for Measuring Reliable Polyp Size

Diagnostic Performance and Sustainability of Using SCALE-EYE During Real-Time Colonoscopy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
241 (estimated)
Sponsor
Erasmus Medical Center · Academic / Other
Sex
All
Age
55 Years – 80 Years
Healthy volunteers
Not accepted

Summary

A multicenter, randomized, parallel group, endoscopist blinded study to assess the diagnostic performance and sustainability of SCALE-EYE in a screening and surveillance colonoscopy population. Sustainability will be evaluated in terms of the reduction in colonoscopies, associated waste and carbon footprint.

Detailed description

Objective: This study aims to assess the diagnostic performance of SCALE-EYE in a screening and surveillance colonoscopy population. Also, sustainability of SCALE-EYE in terms of the reduction in colonoscopies, associated waste and carbon footprint is evaluated. Study design: A multicenter, randomized, parallel group, endoscopist blinded study. Study population: The unit of analysis is the colorectal polyp rather than the participants, approximately 289 colorectal polyps are planned to be included. Based on an expected detection rate of roughly 1.20 polyps per colonoscopy in the study population, approximately 241 participants aged 55-80 years old, who are referred for screening or surveillance colonoscopy at the participating study sites and have signed the informed consent form (ICF), will be included into the study. Polyps of all shapes (flat, sessile, pedunculated) that are found during colonoscopy and are smaller than 25 mm, as judged by the endoscopist using optical assessment, are considered eligible for inclusion. Intervention: Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist and then in a randomized order measured by biopsy-forceps assisted measurement and SCALE-EYE measurement. Primary outcome measurement: The diagnostic performance of SCALE-EYE for polyp size categorization during real-time colonoscopy in comparison to polyp size categorization with biopsy-forceps assisted measurement (the reference standard). This will be measured by accuracy, sensitivity, and specificity of SCALE-EYE categorization compared to size measurement with the reference standard. Secondary outcome measurements: * The diagnostic performance of SCALE-EYE for polyp size categorization during real-time colonoscopy in comparison to optical assessment by endoscopists for polyp size measurement. * Sustainability (reduction of colonoscopies, the colonoscopy-associated waste and carbon footprint). * The learning curve, this will be evaluated by exploring the association between the number of measurements performed and the time needed for measurement and experienced difficulty. * The level of agreement between the endoscopist advised surveillance interval as based on SCALE-EYE, optical assessment, and the reference standard. * Safety, in terms of (serious) adverse events up to 30 days post-procedure.

Conditions

Interventions

TypeNameDescription
DEVICESCALE-EYE (1)Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then with SCALE-EYE and lastly by biopsy-forceps assisted measurement.
DEVICESCALE-EYE (2)Participants will undergo the colonoscopy and once a colorectal polyp is identified, the polyp will first be measured by optical assessment by the endoscopist, then by biopsy-forceps assisted measurement and lastly with SCALE-EYE.

Timeline

Start date
2025-09-23
Primary completion
2026-02-01
Completion
2026-04-01
First posted
2025-06-05
Last updated
2026-01-13

Locations

3 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT07005453. Inclusion in this directory is not an endorsement.